NewsBenzingaRadiopharm Theranostics annuncia il completamento dell’incontro EOP2 con la FDA riguardante RAD101, agente radiofarmaceutico sperimentale per imaging per la rilevazione di metastasi cerebrali Radiopharm Theranostics annuncia il completamento dell’incontro EOP2 con la FDA riguardante RAD101, agente radiofarmaceutico sperimentale per imaging per la rilevazione di metastasi cerebrali Benzinga 2026.10.05 12:09 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target If You Invested $1000 In Ulta Beauty Stock 15 Years Ago, You Would Have This Much Today